Iovance Biotherapeutics (IOVA) investor relations material

Strategic positioning and product portfolio

• Leading innovator in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors, with global rights to its technology platform.

• Two approved products: Amtagvi (lifileucel) for advanced melanoma and Proleukin (aldesleukin) in multiple markets.

• Over 1,500 patients treated with commercial and clinical TIL products.

• More than 90 authorized treatment centers, including expansion into Canada.

• Internal manufacturing facility with capacity for 5,000 patients annually, supporting global supply and logistics.

Financial performance and outlook

• Full-year 2026 revenue guidance of $350M–$370M, with Q2 2026 guidance at $86M–$88M.

• Cash position of $319M as of March 31, 2026, providing runway into 2028.

• Year-over-year quarterly revenue growth of approximately 45%.

• Gross margin of 41% in Q1 2026, impacted by non-recurring costs, with ongoing initiatives to improve margins and cost control.

Clinical data and market opportunity

• Amtagvi is the first FDA-approved one-time, individualized T cell therapy for solid tumor cancer.

• Five-year follow-up in advanced melanoma shows 31.4% ORR, 19.7% OS, and median duration of response of 36.5 months.

• Real-world data demonstrate a 44% ORR and 73% disease control rate, with higher response rates in patients treated earlier.

• Significant unmet need in advanced melanoma, NSCLC, soft tissue sarcomas, and endometrial cancer, with ongoing and planned registrational trials.

• Global NSCLC commercial opportunity estimated at seven times the current melanoma opportunity.